196 related articles for article (PubMed ID: 23821831)
1. Allergen immunotherapy as a drug: the new deal of grass allergen tablets from clinical trials to current practice.
Manzotti G; Lombardi C
Eur Ann Allergy Clin Immunol; 2013 Apr; 45(2):34-42. PubMed ID: 23821831
[TBL] [Abstract][Full Text] [Related]
2. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.
Wessel F; Chartier A; Meunier JP; Magnan A
Clin Drug Investig; 2012 Jul; 32(7):451-63. PubMed ID: 22594491
[TBL] [Abstract][Full Text] [Related]
5. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
6. Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis.
Köberlein J; Mösges R
Immunotherapy; 2013 Jan; 5(1):13-21. PubMed ID: 23256794
[TBL] [Abstract][Full Text] [Related]
7. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial shows sublingual immunotherapy to be effective for treatment of children with grass pollen allergy.
Wilkinson J
Immunotherapy; 2012 Nov; 4(11):1091-2. PubMed ID: 23194357
[No Abstract] [Full Text] [Related]
9. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
Nelson H; Lehmann L; Blaiss MS
Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
[TBL] [Abstract][Full Text] [Related]
10. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
[TBL] [Abstract][Full Text] [Related]
11. An extract of Timothy-grass pollen used as sublingual immunotherapy for summer hay fever.
Kay AB
Drugs Today (Barc); 2007 Dec; 43(12):841-8. PubMed ID: 18174969
[TBL] [Abstract][Full Text] [Related]
12. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
13. SQ-standardised grass tablet sublingual immunotherapy: persistent clinical benefit and progressive immunological changes during three years treatment.
Durham SR
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():121-7; discussion 127-31. PubMed ID: 20799452
[No Abstract] [Full Text] [Related]
14. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
[TBL] [Abstract][Full Text] [Related]
15. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
Larenas-Linnemann D
Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
[TBL] [Abstract][Full Text] [Related]
16. Comments on: "allergen immunotherapy as a drug: the new deal of grass allergen tablets from clinical trials to current practice".
de Beaumont O; Yalaoui T
Eur Ann Allergy Clin Immunol; 2014 May; 46(3):125-6. PubMed ID: 24853574
[No Abstract] [Full Text] [Related]
17. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy.
Calderon MA; Birk AO; Andersen JS; Durham SR
Allergy; 2007 Aug; 62(8):958-61. PubMed ID: 17620076
[TBL] [Abstract][Full Text] [Related]
18. Postmarketing study for assessment of tolerability of a grass allergen immunotherapy tablet (GRAZAX) in patients with rhinitis or rhinoconjunctivitis.
Armentia A; Carballada F; Carretero P; de Paz S; Lobera T; Marcos C; Martínez JC; Rodríguez I; Soto T; Venturini M; de la Torre F
J Investig Allergol Clin Immunol; 2012; 22(7):485-90. PubMed ID: 23397670
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen.
Wüthrich B; Bucher Ch; Jörg W; Bircher A; Eng P; Schneider Y; Schnyder F; Eigenmann P; Senti G
J Investig Allergol Clin Immunol; 2003; 13(3):145-8. PubMed ID: 14635462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
